# Clinical Trials Data ALK - Document 15

# Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)

## Clinical Trial: https://clinicaltrials.gov/study/NCT01662635

"eligibilityCriteria": "Inclusion Criteria:\n\n\* The only inclusion criterion was the availability of tissue for biomarker studies.\n\nExclusion Criteria:\n\n\* Disease Progression",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Mexican pupulation, with Non small-cell lung cancer.",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the clinical trial's eligibility criteria, a patient with an ALK gene mutation would be eligible for the clinical trial, provided they meet the following conditions:  
  
1. They have the availability of tissue for biomarker studies, as this is the sole inclusion criterion mentioned.  
2. They have non-small cell lung cancer (NSCLC), which is the specified study population.  
3. They are at least 18 years old, as the minimum age requirement is 18 years.  
4. They have not experienced disease progression, as this is listed as an exclusion criterion.  
  
Since the presence of an ALK gene mutation is not specified as an exclusion criterion, it does not affect the patient's eligibility. Always consult with a healthcare professional or the study coordinators for the most accurate assessment of eligibility.